​

Immix Biopharma (IMMX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

IMMX Stock Forecast

Immix Biopharma (IMMX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $23.33, with a high of $26.00 and a low of $19.00. This represents a 99.40% increase from the last price of $11.70.

- $6 $12 $18 $24 $30 High: $26 Avg: $23.33 Low: $19 Last Closed Price: $11.7

IMMX Stock Rating

Immix Biopharma stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

IMMX Price Target Upside V Benchmarks

TypeNameUpside
StockImmix Biopharma99.40%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts137
Avg Price Target$26.00$23.33$18.71
Last Closing Price$11.70$11.70$11.70
Upside/Downside122.22%99.40%59.91%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2634---7
Aug, 2634---7
Jul, 2624---6
Jun, 2622---4
May, 2622---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 15, 2026Mizuho Securities$26.00$11.93117.94%122.22%
Aug 11, 2026Morgan Stanley$19.00$10.0888.49%62.39%
Aug 10, 2026Robert BurnsH.C. Wainwright$25.00$9.72157.20%113.68%
May 22, 2026Robert BurnsH.C. Wainwright$20.00$8.92124.22%70.94%
Mar 27, 2026H.C. Wainwright$15.00$8.1584.05%28.21%
Feb 09, 2026Graig SuvannavejhMizuho Securities$14.00$6.74107.72%19.66%
Dec 09, 2025H.C. Wainwright$12.00$6.3888.09%2.56%
Jul 01, 2024Robert BurnsH.C. Wainwright$7.00$1.98253.54%-40.17%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2026CitigroupMarket OutperformMarket Outperformhold
Aug 10, 2026H.C. WainwrightBuyBuyhold
Jul 22, 2026NeedhamBuyinitialise
Jun 18, 2026CitigroupBuyinitialise
Jun 18, 2026Bank of America SecuritiesBuyinitialise
May 22, 2026H.C. WainwrightBuyBuyhold
Mar 27, 2026H.C. WainwrightBuyBuyhold
Mar 25, 2026Morgan StanleyOverweightinitialise
Dec 09, 2025H.C. WainwrightBuyBuyhold
Oct 03, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.89$-0.76$-0.89---
Avg Forecast$-0.80$-0.80$-0.73$-0.37$0.83$2.73
High Forecast$-0.70$-0.66$-0.59$-0.37$0.83$2.73
Low Forecast$-0.88$-0.93$-0.86$-0.37$0.83$2.73
Surprise %11.25%-5.00%21.92%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$1.00M$7.00M$12.14M$85.00M$198.00M
High Forecast-$1.00M$7.00M$12.14M$85.00M$198.00M
Low Forecast-$1.00M$7.00M$12.14M$85.00M$198.00M
Surprise %------

Net Income Forecast

$-30M $-14M $2M $18M $34M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-15.43M$-21.61M$-29.44M---
Avg Forecast$-13.70M$-13.79M$-12.57M$-6.42M$14.39M$47.34M
High Forecast$-12.06M$-11.36M$-10.20M$-6.42M$14.39M$47.34M
Low Forecast$-15.34M$-16.21M$-14.94M$-6.42M$14.39M$47.34M
Surprise %12.60%56.78%134.17%---

IMMX Forecast FAQ

Is Immix Biopharma stock a buy?

Immix Biopharma stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immix Biopharma is a favorable investment for most analysts.

What is Immix Biopharma's price target?

Immix Biopharma's price target, set by 5 Wall Street analysts, averages $23.33 over the next 12 months. The price target range spans from $19 at the low end to $26 at the high end, suggesting a potential 99.40% change from the previous closing price of $11.7.

How does Immix Biopharma stock forecast compare to its benchmarks?

Immix Biopharma's stock forecast shows a 99.40% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Immix Biopharma over the past three months?

  • September 2026: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Immix Biopharma’s EPS forecast?

Immix Biopharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.37, marking a -58.43% decrease from the reported $-0.89 in 2025. Estimates for the following years are $0.83 in 2027, and $2.73 in 2028.

What is Immix Biopharma’s revenue forecast?

Immix Biopharma's average annual revenue forecast for its fiscal year ending in December 2026 is $12.14M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $85M, and $198M for 2028.

What is Immix Biopharma’s net income forecast?

Immix Biopharma's net income forecast for the fiscal year ending in December 2026 stands at $-6.416M, representing a -78.20% decrease from the reported $-29.439M in 2025. Projections indicate $14.39M in 2027, and $47.34M in 2028.